Interleukin-4 receptor (IL-4R) expression on AIDS-related Kaposi's sarcoma (AIDS-KS) cells and inhibition of tumor cell growth and cytokine production by IL-4 (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Interleukin-4 receptor (IL-4R) expression on AIDS-related Kaposi's sarcoma (AIDS-KS) cells and inhibition of tumor cell growth and cytokine production by IL-4 (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A1121 1993. Unique Identifier : AIDSLINE ICDB/93692092
Gill P; Puri PK; Dept. of Medicine, Univ. of Southern California, Los Angeles, CA; 90033

Abstract: We have previously demonstrated that a variety of human solid tumors express high-affinity IL-4R, and IL-4 can inhibit growth of these cells in vitro. In the present study, we have examined (1) the expression of IL-4R on AIDS-KS-derived spindle cells at the tumor cell surface and gene levels and (2) the effect of IL-4 on KS cell growth and regulation of Oncostatin-M and IL-6 expression. AIDS-KS cells expressed 1828 +/- 408 (mean +/- sem) high-affinity IL-4R/cell, with a Kd of 154 +/- 37 pM (mean +/- sem) and expressed in a single 4-kb species of mRNA for IL-4R. IL-4 inhibited KS cell proliferation in vitro in a dose-dependent manner, and this effect was neutralized by anti-IL-4 antibody. IL-4 also decreased the level of immunoreactive IL-6 and steady-state mRNA levels for IL-6 and Oncostatin-M, both of which act as autocrine growth factors for AIDS-KS-derived spindle cells. These results suggest that IL-4 could have therapeutic efficacy in the treatment of AIDS-KS, and the growth-inhibitory effects of IL-4 may be mediated through the inhibition of IL-6 and Oncostatin-M production.

Keywords: Acquired Immunodeficiency Syndrome/*GENETICS/THERAPY Cell Division/DRUG EFFECTS/*GENETICS Cells, Cultured Gene Expression Regulation, Neoplastic/*DRUG EFFECTS Human Interleukin-4/*THERAPEUTIC USE Peptides/GENETICS Receptors, Mitogen/*GENETICS RNA, Messenger/GENETICS Sarcoma, Kaposi's/*GENETICS/THERAPY Skin Neoplasms/*GENETICS/THERAPY ABSTRACT
930730
M9371000

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .